Publications by authors named "Mazaya Fawazy"
Article Synopsis
- Sirolimus-coated balloons (SCBs) show promise for treating de novo lesions, but there is limited long-term data available on their effectiveness and safety.
- This study analyzed outcomes from 771 patients who received SCBs, focusing on metrics like cardiac death, myocardial infarction, and revascularization, with a median follow-up of 640 days.
- Results indicated low rates of adverse events, including a 1.3% rate of cardiac death and 8% overall major adverse cardiac events (MACE), suggesting SCBs may be a viable treatment option in real-world settings.